Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New hope in fight against multi-resistant germs

13.02.2013
International antibiotics study: HZI receives €6m funding
An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can only be treated with a select subset of antibiotics as many drugs have simply stopped working. This is precisely why the field of medicine is in desperate need of new treatment options.

One highly promising drug candidate is now scheduled for testing in clinical trials. The substance, developed by the British pharmaceutical company GlaxoSmithKline, is still known by its rather cryptic working name, GSK1322322. In the course of clinical trials to evaluate new drugs, physicians typically end up with large numbers of patient samples that are invaluable in studying the different diseases patients are suffering from - samples that have, until recently, rarely been recruited for research purposes.

Staphylococcus aureus bacteria, magnified by electron microscopy.
HZI / Rohde

Now, scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, and at the TWINCORE Centre for Experimental and Clinical Infection Research in Hannover, Germany, aim to study such patient samples for a five-year-period. Part of a special collection at the Hannover Medical School's biobank, the samples will allow researchers to find out more about the etiology, course, and characteristic marker substances of infectious diseases. IMI, the Innovative Medicines Initiative, has awarded the scientists research grants totaling 6 million Euros as part of the COMBACTE (Combating Bacterial Resistance in Europe) project. IMI is a joint initiative by the European Union and the pharmaceutical industry.

Dr. Frank Pessler, who heads TWINCORE's “Biomarkers in Infectious Diseases” research group, secured the grant and is the project's coordinator at HZI. Under his helmage, the scientists, along with their colleagues in Paris, Barcelona, and Philadelphia, will be searching for biomarkers - molecules that are unique to a particular disease and which may provide information about if the diagnosis was correct and whether or not the therapy is working.

The new antibiotic, GSK1322322, targets gram-positive bacteria including methicillin-resistant strains of Staphylococcus areus - notorious MRSA - capable of causing serious skin and wound infections. Gram-positive germs are also frequently the culprit behind pneumonia. The drug targets the bacterial enzyme peptide deformylase. Phase I clinical trials, designed to evaluate a new drug's tolerability and safety profile, have already successfully concluded and showed only minor adverse effects. If the next study shows that GSK1322322 does not bestow any added benefit compared to current treatments, it will not be admitted into the next round of clinical trials. "This is where COMBACTE's added scientific value comes into play. In case this happens, the samples that were obtained will still offer insights into the infections they were supposed to treat, and perhaps aid in developing other better treatments" Frank Pessler explains.

Besides Pessler's own group, research teams headed by Prof. Susanne Häussler, Prof. Singh Chhatwal, Prof. Dietmar Pieper, Dr. Eva Medina, Prof. Irene Wagner-Döbler, Dr. Robert Geffers and Prof. Frank Klawonn are also involved in the project. Each team contributes its own special know-how, and, in concert, they are an excellent force. Adds Pessler: "Where else do you find this many experts from all these different disciplines under one roof, some of them even on the same floor? It makes the whole collaboration smooth and efficient."
The Helmholtz Centre for Infection Research:
Scientists at the Helmholtz Centre for Infection Research in Braunschweig, Germany, are engaged in the study of different mechanisms of infection and of the body’s response to infection. Helping to improve the scientific community’s understanding of a given bacterium’s or virus’ pathogenicity is key to developing effective new treatments and vaccines. http://www.helmholtz-hzi.de
TWINCORE, Centre for Experimental and Clinical Infection Research:
At TWINCORE, physicians and scientists from different disciplines are working hand in hand in infection research. The focus is on translational research - at the interface between basic science research and clinical development. TWINCORE is a joint venture by the HZI and MHH, the Hannover Medical School. http://www.twincore.de

GlaxoSmithKline:
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit http://www.gsk.com

Innovative Medicines Initiative:
This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. http://www.imi.europa.eu

List of research affiliates for this sub-project:
Helmholtz Centre for Infection Research, Braunschweig, Germany
TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany
Hannover Medical School, Hannover, Germany
Hospital Clínic de Barcelona, Barcelona, Spain
Faculté de Médecine Necker, Paris, France
GlaxoSmithKline, Philadelphia, USA

Dr. Jan Grabowski | Helmholtz Zentrum
Further information:
http://www.helmholtz-hzi.de
http://www.helmholtz-hzi.de/en/news_events/news/view/article/complete/new_hope_in_fight_against_multi_resistant_germs/

More articles from Studies and Analyses:

nachricht Innovative genetic tests for children with developmental disorders and epilepsy
11.07.2018 | Christian-Albrechts-Universität zu Kiel

nachricht Oxygen loss in the coastal Baltic Sea is “unprecedentedly severe”
05.07.2018 | European Geosciences Union

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Future electronic components to be printed like newspapers

A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.

The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

A smart safe rechargeable zinc ion battery based on sol-gel transition electrolytes

20.07.2018 | Power and Electrical Engineering

Reversing cause and effect is no trouble for quantum computers

20.07.2018 | Information Technology

Princeton-UPenn research team finds physics treasure hidden in a wallpaper pattern

20.07.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>